Prospective CYP2C19 Genotyping to Guide Antiplatelet Therapy Following Percutaneous Coronary Intervention: A Pragmatic Randomized Clinical Trial

Sony Tuteja,Henry A. Glick,William H. Matthai,Irving Nachamkin,Ashwin S. Nathan,Karen Monono,Craig Carcuffe,Karen Maslowski,Gene Chang,Taisei Kobayashi,Saif Anwaruddin,John W. Hirshfeld,Robert L. Wilensky,Howard C. Herrmann,Daniel M. Kolansky,Daniel J. Rader,Jay Giri

Prospective CYP2C19 Genotyping to Guide Antiplatelet Therapy Following Percutaneous Coronary Intervention: A Pragmatic Randomized Clinical Trial

2020

Sony Tuteja
Henry A. Glick
William H. Matthai
Irving Nachamkin
Ashwin S. Nathan
Karen Monono
Craig Carcuffe
Karen Maslowski
Gene Chang
Taisei Kobayashi
Saif Anwaruddin
John W. Hirshfeld
Robert L. Wilensky
Howard C. Herrmann
Daniel M. Kolansky
Daniel J. Rader
Jay Giri

Background - CYP2C19 loss-of-function (LOF) alleles impair clopidogrel effectiveness after percutaneous coronary intervention (PCI), but the clinical impact of implementing CYP2C19 genotyping in a ...

Keywords:

CYP2C19
Conventional PCI
Internal medicine
Genotyping
Percutaneous coronary intervention
Clopidogrel
Randomized controlled trial
Medicine
Clinical trial
Precision medicine
Pharmacogenetics

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations